• News
  • SAN DIEGO
  • BioTech

Isis could gain $2 billion advantage from heart attack study

Isis Pharmaceuticals Inc., a Carlsbad-based maker of gene therapy treatments, may seek to expand use of an experimental drug targeting triglycerides to fight heart disease, a move an analyst says could add $2 billion in sales.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments

Isis Pharmaceuticals Inc.

Company Website

1896 Rutherford Road
Carlsbad, CA 92008

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
ISIS
40.18
  0.25  
+ 0.63%
1,656,962,000
62.66
22.25

Insider Trade Data

Date Insider Shares Type Value
09/19/2014 Isis, Pharmaceuticals Inc 7,700 Sell $321,048
09/19/2014 Isis, Pharmaceuticals Inc 7,700 Sell $321,048
09/02/2014 O, Neil Patrick R 1,500 Sell $60,660
09/02/2014 O, Neil Patrick R 1,500 Exchange $15,435
09/02/2014 Parshall, B Lynne 11,071 Sell $445,507

Isis Pharmaceuticals Inc. Executive(s):

Stanley Crooke

  • Chief Executive Officer, Founder, President, Chairman

Similar Companies

NAICS - 325414 - Biological Product (except Diagnostic) Manufacturing
SIC - 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Subscribe Today!